Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies

NCT00003406 is registered in ClinicalTrials.gov with Cancer Treatment Centers of America as lead sponsor.

NCT NCT00003406
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00003406 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies
Lead sponsor
Cancer Treatment Centers of America
Phase
Phase 1/2
Overall status
Completed
Start date
October 31, 1997
Completion date
March 31, 2000
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myeloproliferative disorders, leukemia, lymphoma, multiple myeloma and plasma cell neoplasm, myelodysplastic syndromes, precancerous/nonmalignant condition, unspecified adult solid tumor, protocol specific